Compare Stocks: IBIO, ALXO, TRDA, and YDES

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$2.06 -1.0%	$1.94	$0.80 ▼ $2.66	$287.62M	0.42	1.08 million shs	1.22 million shs
IBIO iBio	$1.49 +2.8%	$1.52	$0.72 ▼ $3.82	$72.04M	1.3	702,579 shs	837,918 shs
TRDA Entrada Therapeutics	$7.78 +7.0%	$6.99	$5.02 ▼ $16.45	$283.07M	-0.26	411,480 shs	241,835 shs
YDES YD Bio	$4.47 +12.3%	$2.49	$1.70 ▼ $25.00	$281.74M	N/A	41,375 shs	83,898 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-0.96%	+2.49%	+7.29%	+3.52%	+131.46%
IBIO iBio	+2.76%	+1.36%	+8.76%	-21.16%	+148,999,900.00%
TRDA Entrada Therapeutics	+7.02%	+1.43%	+22.71%	+23.30%	+38.43%
YDES YD Bio	+12.31%	+71.92%	+96.92%	-1.11%	+446,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$2.06 -1.0%	$1.94	$0.80 ▼ $2.66	$287.62M	0.42	1.08 million shs	1.22 million shs
IBIO iBio	$1.49 +2.8%	$1.52	$0.72 ▼ $3.82	$72.04M	1.3	702,579 shs	837,918 shs
TRDA Entrada Therapeutics	$7.78 +7.0%	$6.99	$5.02 ▼ $16.45	$283.07M	-0.26	411,480 shs	241,835 shs
YDES YD Bio	$4.47 +12.3%	$2.49	$1.70 ▼ $25.00	$281.74M	N/A	41,375 shs	83,898 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-0.96%	+2.49%	+7.29%	+3.52%	+131.46%
IBIO iBio	+2.76%	+1.36%	+8.76%	-21.16%	+148,999,900.00%
TRDA Entrada Therapeutics	+7.02%	+1.43%	+22.71%	+23.30%	+38.43%
YDES YD Bio	+12.31%	+71.92%	+96.92%	-1.11%	+446,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	123.30% Upside
IBIO iBio	3.13	Buy	$5.00	235.57% Upside
TRDA Entrada Therapeutics	2.50	Moderate Buy	$17.75	128.15% Upside
YDES YD Bio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest IBIO, ALXO, TRDA, and YDES Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	TRDA Entrada Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/2/2026	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
6/26/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/11/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
6/8/2026	TRDA Entrada Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$20.00 ➝ $17.00
6/8/2026	IBIO iBio	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/8/2026	IBIO iBio	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/5/2026	IBIO iBio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.98 per share	N/A
IBIO iBio	$300K	246.74	N/A	N/A	$0.90 per share	1.66
TRDA Entrada Therapeutics	$25.42M	11.92	N/A	N/A	$5.99 per share	1.30
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
IBIO iBio	-$18.38M	-$0.58	N/A	N/A	N/A	N/A	-53.86%	-46.48%	9/4/2026 (Estimated)
TRDA Entrada Therapeutics	-$143.75M	-$3.96	N/A	N/A	N/A	-3,537.73%	-57.61%	-46.54%	11/5/2026 (Estimated)
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IBIO, ALXO, TRDA, and YDES Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	Q4 2026	IBIO iBio	-$0.07	N/A	N/A	N/A	$0.08 million	N/A
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
8/5/2026	Q2 2026	TRDA Entrada Therapeutics	-$0.9738	-$1.01	-$0.0363	-$1.01	$2.32 million	$0.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.07	9.71	9.71
IBIO iBio	N/A	11.88	11.88
TRDA Entrada Therapeutics	N/A	10.89	10.89
YDES YD Bio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
IBIO iBio	7.90%
TRDA Entrada Therapeutics	86.39%
YDES YD Bio	N/A

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	12.40%
IBIO iBio	2.75%
TRDA Entrada Therapeutics	9.49%
YDES YD Bio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	138.28 million	121.13 million	Optionable
IBIO iBio	100	49.68 million	48.31 million	N/A
TRDA Entrada Therapeutics	110	38.94 million	35.24 million	Optionable
YDES YD Bio	N/A	70.79 million	N/A	N/A

IBIO, ALXO, TRDA, and YDES Headlines

Recent News About These Companies

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...

August 11, 2026 | markets.businessinsider.com

YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem

August 11, 2026 | tipranks.com

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

August 4, 2026 | markets.businessinsider.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

July 28, 2026 | finance.yahoo.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

July 24, 2026 | markets.businessinsider.com

YD Bio Limited

July 15, 2026 | cnn.com

YD Bio Limited Ordinary Shares (YDES) Insider Activity

July 14, 2026 | nasdaq.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

July 2, 2026 | globenewswire.com

YD Bio Ltd.

June 25, 2026 | barrons.com

Yd Bio

June 25, 2026 | fool.com

YD Bio Analyst Ratings and Price Targets | NASDAQ:YDES | Benzinga

June 25, 2026 | benzinga.com

YD Bio Limited Reports Financial Results for Full Year 2025, Achieves 17% Revenue Growth and Strategic Advances in Healthcare Innovations

April 30, 2026 | quiverquant.comQ

YD Bio Limited Reports Full Year 2025 Financial Results

April 30, 2026 | globenewswire.com

YD Bio Ltd YDES

April 4, 2026 | morningstar.comM

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

March 31, 2026 | globenewswire.com

YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

March 17, 2026 | globenewswire.com

YD Bio Forms Taiwan-U.S. Dual-Core FDA Regulatory Platform in Alliance with YC Biotech

February 26, 2026 | tipranks.com

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

February 25, 2026 | globenewswire.com

YDES YD Bio Limited

February 25, 2026 | seekingalpha.com

YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC

January 30, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, ALXO, TRDA, and YDES Company Descriptions

ALX Oncology NASDAQ:ALXO

$2.06 -0.02 (-0.96%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$2.04 -0.02 (-0.97%)

As of 04:33 AM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

iBio NASDAQ:IBIO

$1.49 +0.04 (+2.76%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$1.48 -0.01 (-1.01%)

As of 04:21 AM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Entrada Therapeutics NASDAQ:TRDA

$7.78 +0.51 (+7.02%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$7.77 -0.01 (-0.13%)

As of 08/19/2026 07:30 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

YD Bio NASDAQ:YDES

$4.47 +0.49 (+12.31%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$4.47 +0.00 (+0.11%)

As of 04:03 AM Eastern

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBIO, ALXO, TRDA, and YDES Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBIO, ALXO, TRDA, and YDES Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBIO, ALXO, TRDA, and YDES Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, ALXO, TRDA, and YDES Company Descriptions

ALX Oncology NASDAQ:ALXO

iBio NASDAQ:IBIO

Entrada Therapeutics NASDAQ:TRDA

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBIO, ALXO, TRDA, and YDES Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBIO, ALXO, TRDA, and YDES Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBIO, ALXO, TRDA, and YDES Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, ALXO, TRDA, and YDES Company Descriptions

ALX Oncology NASDAQ:ALXO

iBio NASDAQ:IBIO

Entrada Therapeutics NASDAQ:TRDA

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools